What is Maxygen?
Maxygen is a prominent biotechnology firm headquartered in the San Francisco Bay Area, specializing in the cutting-edge fields of directed evolution and molecular breeding technology. The company excels in generating diverse genetic libraries with high functional content, providing an economical pathway for directed evolution screening campaigns. Maxygen offers comprehensive molecular biology services, including advanced DNA synthesis and cloning techniques, to support partner project development without the partners retaining ownership of the intellectual property or outcomes. Their pioneering methodologies are instrumental in enhancing protein functionality across a broad spectrum of biotechnological applications.
How much funding has Maxygen raised?
Maxygen has raised a total of $96K across 1 funding round:
Debt
$96K
Debt (2021): $96K with participation from PPP
Key Investors in Maxygen
PPP
Public-Private Partnership
What's next for Maxygen?
With substantial expansion capital, Maxygen is poised to further its research and development initiatives, potentially scaling its operations and broadening its market reach. The company's focus on directed evolution and molecular breeding suggests strategic investments in enhancing its proprietary platforms and expanding its service offerings to the biotechnology sector. Future endeavors may include forging new strategic partnerships, advancing its pipeline of novel molecular solutions, and solidifying its position as a leader in genetic diversity and protein engineering.
See full Maxygen company page
